# BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

> **NCT02209753** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 182 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BIRB 796 BS, low dose
- **DRUG:** BIRB 796 BS, medium dose 1
- **DRUG:** BIRB 796 BS, medium dose 2
- **DRUG:** BIRB 796 BS, high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02209753
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2002-09
- **Final completion:** —
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209753, "BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02209753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*